Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROOT study of oral MGT-006 in moderately active ulcerative colitis
jRCT2071260030Phase 2Recruiting
- Sponsor
- Metagen Therapeutics, Inc.
- Start
- Aug 2026
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of MGT-006 in autoimmune colitis (3 arms), sponsored by Metagen Therapeutics, Inc. Primary endpoint: Safety and tolerability. Started Aug 2026; status: recruiting.
02
Drugs
MGT-006
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2071260030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260030.